Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Industry
  • 1.7 COVID-19 Impact: Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Trends

    • 2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Market Size Analysis

    • 2.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Business Impact Assessment - COVID-19
      • 2.1.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market
    • 3.5 Key Manufacturers Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Aloxi (palonosetron)
      • 1.4.2 Kytril Generic (granisetron)
      • 1.4.3 Emend (aprepitant)
      • 1.4.4 Akynzeo (netupitant-palonosetron)
    • 4.2 By Type, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, 2019-2021
      • 4.2.1 By Type, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price, 2020-2021

    5 Impact of Covid-19 on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Segments, By Application

    • 5.1 Overview
      • 5.5.1 Blood Cancer
      • 5.5.2 Breast Cancer
      • 5.5.3 Gastrointestinal Tract Cancer
      • 5.5.4 Others
    • 5.2 By Application, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, 2019-2021
      • 5.2.1 By Application, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 GlaxoSmithKline
      • 7.1.1 GlaxoSmithKline Business Overview
      • 7.1.2 GlaxoSmithKline Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.1.3 GlaxoSmithKline Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.1.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.2 Helsinn
      • 7.2.1 Helsinn Business Overview
      • 7.2.2 Helsinn Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.2.3 Helsinn Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.2.4 Helsinn Response to COVID-19 and Related Developments
    • 7.3 Heron Therapeutics
      • 7.3.1 Heron Therapeutics Business Overview
      • 7.3.2 Heron Therapeutics Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.3.3 Heron Therapeutics Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.3.4 Heron Therapeutics Response to COVID-19 and Related Developments
    • 7.4 Merck & Co
      • 7.4.1 Merck & Co Business Overview
      • 7.4.2 Merck & Co Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.4.3 Merck & Co Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.4.4 Merck & Co Response to COVID-19 and Related Developments
    • 7.5 Tesaro
      • 7.5.1 Tesaro Business Overview
      • 7.5.2 Tesaro Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.5.3 Tesaro Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.5.4 Tesaro Response to COVID-19 and Related Developments
    • 7.6 Acacia Pharma
      • 7.6.1 Acacia Pharma Business Overview
      • 7.6.2 Acacia Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.6.3 Acacia Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.6.4 Acacia Pharma Response to COVID-19 and Related Developments
    • 7.7 Aphios
      • 7.7.1 Aphios Business Overview
      • 7.7.2 Aphios Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.7.3 Aphios Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.7.4 Aphios Response to COVID-19 and Related Developments
    • 7.8 Barr Laboratories
      • 7.8.1 Barr Laboratories Business Overview
      • 7.8.2 Barr Laboratories Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.8.3 Barr Laboratories Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.8.4 Barr Laboratories Response to COVID-19 and Related Developments
    • 7.9 Baxter Healthcare
      • 7.9.1 Baxter Healthcare Business Overview
      • 7.9.2 Baxter Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.9.3 Baxter Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.9.4 Baxter Healthcare Response to COVID-19 and Related Developments
    • 7.10 Eisai
      • 7.10.1 Eisai Business Overview
      • 7.10.2 Eisai Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.10.3 Eisai Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.10.4 Eisai Response to COVID-19 and Related Developments
    • 7.11 Especificos Stendhal
      • 7.11.1 Especificos Stendhal Business Overview
      • 7.11.2 Especificos Stendhal Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.11.3 Especificos Stendhal Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.11.4 Especificos Stendhal Response to COVID-19 and Related Developments
    • 7.12 F.Hoffmann La Roche
      • 7.12.1 F.Hoffmann La Roche Business Overview
      • 7.12.2 F.Hoffmann La Roche Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.12.3 F.Hoffmann La Roche Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.12.4 F.Hoffmann La Roche Response to COVID-19 and Related Developments
    • 7.13 Mundipharma
      • 7.13.1 Mundipharma Business Overview
      • 7.13.2 Mundipharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.13.3 Mundipharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.13.4 Mundipharma Response to COVID-19 and Related Developments
    • 7.14 Mylan Pharmaceuticals
      • 7.14.1 Mylan Pharmaceuticals Business Overview
      • 7.14.2 Mylan Pharmaceuticals Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.14.3 Mylan Pharmaceuticals Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.14.4 Mylan Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.15 OPKO Health
      • 7.15.1 OPKO Health Business Overview
      • 7.15.2 OPKO Health Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.15.3 OPKO Health Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.15.4 OPKO Health Response to COVID-19 and Related Developments
    • 7.16 Orchid Healthcare
      • 7.16.1 Orchid Healthcare Business Overview
      • 7.16.2 Orchid Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.16.3 Orchid Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.16.4 Orchid Healthcare Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Supply Chain Analysis
      • 8.1.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Distribution Channels
      • 8.2.2 Covid-19 Impact on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Distribution Channels
      • 8.2.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Distributors
    • 8.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs, including the following market information:
      Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

      Key market players
      Major competitors identified in this market include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co, Tesaro, Acacia Pharma, Aphios, Barr Laboratories, Baxter Healthcare, Eisai, Especificos Stendhal, F.Hoffmann La Roche, Mundipharma, Mylan Pharmaceuticals, OPKO Health, Orchid Healthcare, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Aloxi (palonosetron)
      Kytril Generic (granisetron)
      Emend (aprepitant)
      Akynzeo (netupitant-palonosetron)

      Based on the Application:
      Blood Cancer
      Breast Cancer
      Gastrointestinal Tract Cancer
      Others

      Buy now